Karin Rosen
Förmögenhet: 1 068 $ per 2026-08-31
Förmögenhet: 1 068 $ per 2026-08-31
Currently, Karin Rosen is Director at Diamyd Medical AB since 2023 and Chief Scientific Officer at Horizon Therapeutics Ltd. (Ireland) since 2020.
Formerly, Dr. Rosen was Senior Vice President-US Medical Affairs at GSK Plc from 2018 to 2020.
Education includes a doctorate from the University of Lund.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
| 2025-08-31 | 10 000 ( 0,01 % ) | 1 068 $ | 2026-08-31 |
| Företag | Position | Start |
|---|---|---|
| DIAMYD MEDICAL AB | Direktör/Styrelseledamot | 2023-03-10 |
| Företag | Position | Slut |
|---|---|---|
| GSK PLC | Företagsledare/Principal | 2020-11-01 |
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Teknisk/Vetenskaplig/F&U Direktör | - |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 4 |
|---|---|
Horizon Therapeutics Ltd. (Ireland)
Horizon Therapeutics Ltd. (Ireland) Pharmaceuticals: MajorHealth Technology Discovers, develops and manufactures pharmaceuticals for autoimmune & inflammatory diseases | Health Technology |
GSK Plc
GSK Plc Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes vaccines and other pharmaceutical products | Health Technology |
University of Lund
University of Lund Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Diamyd Medical AB
Diamyd Medical AB Pharmaceuticals: MajorHealth Technology Develops precision medicine drugs for type 1 diabetes and other forms of autoimmune diabetes | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån